Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer

Overview

The goal of this proposal is to determine whether a hand-held confocal microscopy probe may perform better than standard methods in detecting cancer or pre-cancerous abnormalities of the cervix. The confocal probe will provide invivo histopathology-like images of cell morphology and three-dimensional tissue architecture non-invasively in real time.

Full Title of Study: “Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2019

Detailed Description

All subjects will undergo standard management (colposcopy) for their cervical lesion as scheduled. For cervical sites suspicious of dysplasia, acriflavine hydrochloride 0.05% solution will be applied topically, then rinsed with saline prior to in vivo confocal imaging with the hand-held probe. Following that, a biopsy of the suspicious site will be performed irrespective of the confocal microscopy finding. A biopsy of the normal site will be taken for research purposes. The confocal probe imaging will not alter where and how the biopsies will be taken (no change to size of biopsy or location on cervix). The procedure will add approximately 15 minutes to the duration of the standard outpatient procedure. During each examination, the anatomical location of all tissue areas in question will be recorded using the clock-position nomenclature system. Some normal areas will be also localized and recorded as control. Digital images will be recorded in the computer.

Interventions

  • Device: In Vivo Confocal Microscopy Probe
    • Participants will have 2 areas on their cervical imaged by the confocal probe.

Arms, Groups and Cohorts

  • Initial Colposcopy Visit
    • Women with a scheduled colposcopy and biopsy appointment at the Women’s Clinic at Vancouver General Hospital

Clinical Trial Outcome Measures

Primary Measures

  • Detection of pre-cancer abnormalities of the cervix by the confocal microscopy probe
    • Time Frame: Probe measurements on participant’s cervix should take no more than 10 minutes during the clinical visit

Participating in This Clinical Trial

Inclusion Criteria

  • indicate understanding of the study – provide informed consent to participate – 18 years old or older – not pregnant and have negative urine pregnancy test – be schedule for colposcopy & biopsy at the Vancouver General Hospital Women's Clinic Exclusion Criteria:

  • they are breast-feeding – they had an operation to remove their cervix

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • British Columbia Cancer Agency
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marette Lee, MD, Principal Investigator, BC Cancer Agency, Gynecologic Oncology

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.